DE69434617D1 - Verfahren zur prophylaxe oder kontrolle des katarakts - Google Patents

Verfahren zur prophylaxe oder kontrolle des katarakts

Info

Publication number
DE69434617D1
DE69434617D1 DE69434617T DE69434617T DE69434617D1 DE 69434617 D1 DE69434617 D1 DE 69434617D1 DE 69434617 T DE69434617 T DE 69434617T DE 69434617 T DE69434617 T DE 69434617T DE 69434617 D1 DE69434617 D1 DE 69434617D1
Authority
DE
Germany
Prior art keywords
cataract
prophylaxis
procedure
control
tgfbeta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434617T
Other languages
English (en)
Inventor
Johnston William Mcavoy
Coral Gwenda Chamberlain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sydney filed Critical University of Sydney
Application granted granted Critical
Publication of DE69434617D1 publication Critical patent/DE69434617D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
DE69434617T 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts Expired - Lifetime DE69434617D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM254093 1993-11-19
PCT/AU1994/000694 WO1995013827A1 (en) 1993-11-19 1994-11-11 A method for preventing or controlling cataract

Publications (1)

Publication Number Publication Date
DE69434617D1 true DE69434617D1 (de) 2006-04-06

Family

ID=3777368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434617T Expired - Lifetime DE69434617D1 (de) 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts

Country Status (6)

Country Link
US (1) US20030130324A1 (de)
EP (1) EP0735895B1 (de)
JP (1) JPH09505057A (de)
AT (1) ATE315939T1 (de)
DE (1) DE69434617D1 (de)
WO (1) WO1995013827A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
CA2267320A1 (en) * 1996-10-14 1998-04-23 Hiroshi Miyata Secondary cataract inhibitor
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
AU2003297511B2 (en) * 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20080075756A1 (en) * 2004-06-30 2008-03-27 Advanced Medical Optics, Inc. Enhancement of lens regeneration using materials comprising polymers
US20060083732A1 (en) * 2004-06-30 2006-04-20 Arlene Gwon Hyaluronic acid in the enhancement of lens regeneration
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
AU2006270094A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Prevention and treatment of ophthalmic complications of diabetes
EP2010100B1 (de) * 2006-04-27 2018-11-28 Johnson & Johnson Surgical Vision, Inc. Materialien mit polysiloxan-polymeren zur verbesserten linsenregeneration
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
RU2510274C2 (ru) * 2008-05-07 2014-03-27 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Терапевтическое восстановление и усиление увлажнения поверхности глаза
EP2949752B1 (de) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Selbstfreisetzende rnai-verbindungen von reduzierter grösse
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2512492A1 (de) 2009-12-14 2012-10-24 University of Massachusetts Verfahren zur hemmung von grauem star und altersweitsichtigkeit
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
EP3578183B1 (de) 2010-03-24 2021-09-08 Phio Pharmaceuticals Corp. Rna-interferenz bei augenerkrankungen
EA029070B1 (ru) 2013-03-14 2018-02-28 Дзе Юниверсити Оф Массачусетс Способ задержки развития катаракты и пресбиопии
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
US10736863B2 (en) 2015-11-13 2020-08-11 University Of Massachusetts Methods of inhibiting cataracts and presbyopia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61233622A (ja) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd 眼薬組成物
SU1500254A1 (ru) * 1986-01-10 1989-08-15 Ростовский медицинский институт Способ прогнозировани осложнений после операции экстракции стационарных травматических катаракт
US5338545A (en) * 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5290813A (en) * 1987-06-04 1994-03-01 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
DE3883712T2 (de) * 1987-06-04 1993-12-16 Massachusetts Inst Technology Chemisches verhindern oder rückgängigmachen von star-erkrankungen durch phasentrennungsinhibitoren.
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
FR2627078B1 (fr) * 1988-02-16 1994-03-18 Allergan Inc Dispositif oculaire
DE68921436T2 (de) * 1988-12-09 1995-08-10 Allergan Inc Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.
EP0491860B1 (de) * 1989-09-15 1997-01-15 Chiron Vision Corporation Synthetisches material, das die anlagerung, das wachstum und die befestigung von epithelzellen fördert, prosthetische vorrichtung zur subepithelialen implantation sowie behandelte linse
DK0494264T3 (da) * 1989-09-29 1998-01-26 Jolla Cancer Res Found Inhibering af transformede vækstfaktor til hindring af akkumulation af ekstracellulær matrix
TW249226B (de) * 1990-04-04 1995-06-11 Aderk Ueno Kk
US5164187A (en) * 1990-04-05 1992-11-17 Norian Corporation Hydroxyapatite prosthesis coatings
EP0489185B1 (de) * 1990-12-03 1996-06-26 Chiron Adatomed Pharmazeutische und Medizintechnische Gesellschaft mbH Intraokulare künstliche Augenlinse
IT1249047B (it) * 1991-02-21 1995-02-11 Zambon Spa Composizione farmaceutica per il trattamento della cataratta
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
IT1251838B (it) * 1991-09-20 1995-05-26 Lpb Ist Farm Uso della nimesulide nel trattamento della cataratta
AU669132B2 (en) * 1991-10-11 1996-05-30 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
EP1230929A1 (de) * 1991-11-14 2002-08-14 La Jolla Cancer Research Foundation Inhibitoren von Zellregulationsfaktoren und Verfahren zur Vorbeugung oder Verminderung von Narbenbildung
WO1993010808A1 (en) * 1991-12-04 1993-06-10 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
WO1993021945A1 (en) * 1992-04-23 1993-11-11 The Regents Of The University Of California METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
CA2138644A1 (en) * 1992-07-08 1994-01-20 Bert M. Glaser Method of treating ophthalmic disorders using tgf-.beta.
US5589464A (en) * 1992-09-01 1996-12-31 Allergan Use of 2-substituted-thiazolidine-4-carboxylic acids for treatment of cataract
DE69332026T2 (de) * 1992-10-29 2002-10-31 Celtrix Pharma Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
AU5541094A (en) * 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis

Also Published As

Publication number Publication date
WO1995013827A1 (en) 1995-05-26
US20030130324A1 (en) 2003-07-10
ATE315939T1 (de) 2006-02-15
EP0735895B1 (de) 2006-01-18
EP0735895A1 (de) 1996-10-09
EP0735895A4 (de) 2001-03-28
JPH09505057A (ja) 1997-05-20

Similar Documents

Publication Publication Date Title
DE69434617D1 (de) Verfahren zur prophylaxe oder kontrolle des katarakts
DE69230242T2 (de) Verfahren zur Reinigung von Hyaluronsäure und Fraktion von reiner Hyaluronsäurezur ophthalmischen Verwendung.
NZ255758A (en) Crosslinked polymeric ammonium salts useful as bile sequestrants
DE59807122D1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
ZA958145B (en) Inhibition of hair growth
DE69423782D1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
CA2155407A1 (en) Surface modified silica
UA41275C2 (uk) Гербіцидна композиція та спосіб контролю росту небажаних рослин
AU6008894A (en) Hypolipidaemic compounds
GR3034407T3 (en) Skin tanning compositions
DE69727839D1 (de) Verwendung von zusammensetzungen zur versorgung mit mineralien nach einer gastrotomie
DE69112814D1 (de) Verfahren zur korrigierung und optimierung einer futterzusammensetzung.
ATE175999T1 (de) Verfahren zur regulierung von sialinsaeurederivaten in rekombinanten glykoproteinen
DE69510775D1 (de) Methoden zur verwendung von cyclischenpolyanionischen polyderivatenzur kontrolle von hautfalten
ATE148074T1 (de) Verfahren zur kontrolle von schwingungen einer pendelnden last und vorrichtung zur durchführung des verfahrens
GB9410639D0 (en) Method of improving fertilization
DE69707155D1 (de) Verfahren zur herstellung eines kornorientierten siliziumstahlblechs
DE69228814D1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69512903T2 (de) Für die vermeidung/begrenzung von mikrobiologisch beeinflusster korrosion und verfärbung verwendbare borate
AU2001254634A1 (en) Use of neuregulin-beta as an indicator and/or target
HU9204171D0 (en) Method for producing aralkyl esters of 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-anthracene-carboxylic acid as well as medical preparatives containing them
DE69210286D1 (de) Behandlung von intraocularem Druck mit einer synergistischen Kombination
EP0344995A3 (de) Methode zur Verhinderung des Verlustes kognitiver Funktionen durch Anwendung eines Kalzium-Kanal-Blockers alleine oder in Kombination mit einem ACE-Inhibitor
ES8900224A1 (es) Un procedimiento para la preparacion de un hidrolizado proteinico.
EP0402312A3 (de) P-substituierte Propanphosphinsäureverbindungen

Legal Events

Date Code Title Description
8332 No legal effect for de